A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine
about
Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genesAssociations between single nucleotide polymorphisms in cellular viral receptors and attachment factor-related genes and humoral immunity to rubella vaccination.Seroprevalence of Measles Antibodies and Predictors for Seropositivity among Chinese Children.Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptidesProfiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays.Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccinationAssociations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination.Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes.Independence of measles-specific humoral and cellular immune responses to vaccinationReplication of associations between cytokine and cytokine receptor single nucleotide polymorphisms and measles-specific adaptive immunophenotypic extremesWhole Transcriptome Profiling Identifies CD93 and Other Plasma Cell Survival Factor Genes Associated with Measles-Specific Antibody Response after Vaccination.A large population-based association study between HLA and KIR genotypes and measles vaccine antibody responses.Variability in Humoral Immunity to Measles Vaccine: New Developments.The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approachesAssociations between polymorphisms in the antiviral TRIM genes and measles vaccine immunity.Delayed adaptive immunity is related to higher MMR vaccine-induced antibody titers in childrenIn Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines?Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine.Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts.Measles vaccine: Past, present, and future.Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine.Genetically defined race, but not sex, is associated with higher humoral and cellular immune responses to measles vaccination.Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells.Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.Outbreak of measles among persons with prior evidence of immunity, New York City, 2011.Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination.Biophysical Properties and Antiviral Activities of Measles Fusion Protein Derived Peptide Conjugated with 25-Hydroxycholesterol.Heritability of vaccine-induced measles neutralizing antibody titers.
P2860
Q26782411-5396C02A-FADD-4D23-BCC0-6D28405E1FCCQ33778981-A20B6955-4EAA-4632-989D-5CA54C14E29CQ33839703-6BD74449-325C-47B2-B2BA-3A425BC11640Q34991022-205EEB00-14AB-4CE4-9D3C-4D9E205D909DQ35232801-2481F726-E31B-4ABC-9FCE-5C4920CC60BAQ35318219-E167DC15-8524-4DA9-9589-52AF5DA95826Q35731350-F230BDAD-5075-4620-929C-7788C4E3A9FFQ35784185-540760F1-95C8-47BD-8E44-5DA7430ACE38Q35918575-99B8F406-F605-4E4D-AC2C-476E0903ADCDQ36010709-03D52D19-0DDB-4BF4-BC6C-348AB32C8F70Q36105040-94367199-7ECD-4369-AF8E-8EAE933567BBQ36269765-CDFA6B95-0E34-4C69-9043-F2C26B723597Q36373260-D53DDFE1-E7D2-4AD0-923E-F406CCB8F2DEQ36603325-165C6E9B-9AAD-4C35-AD8A-C2EF18CD0F1AQ36816196-D0F67E6C-ACE4-45B7-9833-FD0B4913A052Q36865091-24564D26-46A3-415C-9167-D4B9FC71D827Q37512939-23F40D46-8E80-45CB-9A27-B08A5B4F473DQ37526764-97A1E0D6-BBE6-41B8-AC51-6DB1199893EEQ37616442-D2C47CE0-779D-485A-B100-ED1F0F406B71Q37693231-27A876AC-BB8D-42C1-946C-2DB6B8881C21Q38560170-38275882-01EC-4075-9D68-5482B1CC5F94Q38910093-B1C7EB9A-6066-4BED-81E0-238D90AEC5B1Q38945450-DF79FE7F-AADF-43D0-99BD-F949F55B9833Q39221090-4DD78B3E-4862-4347-94BE-DDB6E8D62904Q40285941-D21811E2-DE98-45AC-B781-BBC642396260Q40349772-5407734D-AF44-421B-8C95-65783D6431C5Q42226296-C1E93504-8481-4619-A409-CE72FD3EEB06Q47547879-FB0054E7-FBCE-4048-9F71-0ED9D14D4E59Q47582990-0039024D-A8D2-4FAE-A698-D7566BB746B0Q47892454-F57D9DC8-A58B-4144-A00F-996FD91405C9
P2860
A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A large observational study to ...... owing two doses of MMR vaccine
@ast
A large observational study to ...... owing two doses of MMR vaccine
@en
type
label
A large observational study to ...... owing two doses of MMR vaccine
@ast
A large observational study to ...... owing two doses of MMR vaccine
@en
prefLabel
A large observational study to ...... owing two doses of MMR vaccine
@ast
A large observational study to ...... owing two doses of MMR vaccine
@en
P2093
P2860
P50
P1433
P1476
A large observational study to ...... owing two doses of MMR vaccine
@en
P2093
Megan O'Byrne
Robert M Jacobson
V Shane Pankratz
P2860
P304
P356
10.1016/J.VACCINE.2011.04.037
P407
P577
2011-05-01T00:00:00Z